5 results about "Tumor angiogenesis" patented technology

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of the drug comprise the clostridium ghonii and the tumor angiogenesis inhibitor.

The application discloses a kind of tumor angiogenesis simulation methods, including the blood vessel network topology including environment pixel point and blood vessel pixel point generated based on the medical image of patient;Based on the average path length and step length adjustment factor, chemotaxis weight, bifurcation number range and bifurcation probability of related data such as blood vessel tip of blood vessel network topology are constantly updated;And the bifurcation number of each iteration blood vessel tip and the branch length of each branch after bifurcation are calculated based on the update result of each iteration, and the update of blood vessel network topology is completed based on the bifurcation number and the branch length of each branch after bifurcation calculated, constantly circulate until reaching simulation condition.The application quantifies the transport efficiency of blood vessel network by global function index average path length, realizes the evaluation whether blood vessel network presents efficient local characteristics by clustering coefficient and average path length, guarantees that the blood vessel network obtained by simulation is same with real network.

The application discloses an NGR peptide coupled ruthenium complex and a preparation method and application thereof, and belongs to the technical field of tumor photodynamic therapy. The application couples NGR peptide and a two-photon active ruthenium complex to construct a double-targeted photosensitizer. The NGR oligopeptide can specifically combine with CD13 receptors which are highly expressed on the surface of tumor vascular endothelial cells and tumor cells, realize double targeting of'vessel+tumor cell', and significantly improve the tumor enrichment efficiency of drugs. The NGR peptide coupled ruthenium complex provided by the application can efficiently generate active oxygen under the excitation of 820 nm near-infrared light, specifically kill CD13 positive target cells, and the tissue penetration depth can reach 250 microns, which is suitable for deep tumor treatment. Meanwhile, the NGR peptide coupled ruthenium complex can efficiently destroy the pipe forming ability of vascular endothelial cells, and significantly inhibit tumor angiogenesis.

The present disclosure relates to an anti-VEGF-anti-PD-1 multispecific antibody, a pharmaceutical composition of same, and uses thereof. The multispecific antibody may activate the immune system and block tumor angiogenesis simultaneously, thus providing increased antitumor properties.